FDA’s groundbreaking handheld counterfeit detection device (CD-3) has been awarded a patent, according to a just-issued report by Securing Industry. The question I have is why this process took so long. This amazing device is relatively inexpensive and highly portable. It’s also extremely versatile and effective. How many devices that fit these criteria have the potential to field-test product as well as packaging for signs of counterfeiting and diversion? Few, if any, I suspect. I was one of the earliest proponents of this device within FDA and worked closely with its creators at the Forensic Chemistry Center to develop specialized training for FDA’s criminal investigative unit. Unfortunately, the timing was not right and our efforts largely fizzled. But maybe CD-3’s time has finally come. If given the chance to show its stuff to a wide audience, I’m convinced it will not disappoint (see my previous CD-3 posts here, here, and here).
- FDA’S OCTOBER 2017 COUNTERFEIT HARVONI NOTICE UNCOVERED February 7, 2018
- FDA’S OFFICE OF CRIMINAL INVESTIGATIONS FACING AN UNCERTAIN FUTURE February 1, 2018
- COUNTERFEIT PRESCRIPTION DRUGS AND FENTANYL-INTERNATIONAL MAIL VULNERABILITIES EXPOSED January 27, 2018
- FDA DRUG SHORTAGE STATEMENT TARGETS HOARDING BY HEALTHCARE PROVIDERS November 23, 2017
- PHARMACY VP CHARGED IN PA DRUG RECYCLING DIVERSION SCHEME October 12, 2017
- OUR AILING SUPPLY CHAIN NEEDS A PANGEA-STYLE FDA OPERATION OF ITS OWN October 10, 2017